Lonza can help you
navigate the complex regulatory environment with our unmatched expertise:
Lonza offers actives substances and
formulated products for medical device applications as well as
antimicrobial ingredients for medicinal products / drug-device combinations.
The EU Biocidal
Product Regulation (EU) No 528/2012 (BPR) has introduced significant changes in
the regulation and authorisation of biocidal products that will impact your
product portfolio. Once an active substance has been evaluated as acceptable
for inclusion in the Union List of allowable substances, the product
authorisation phase of the BPR will become relevant for companies wishing to
place and keep biocidal products (including disinfectants) containing listed
substances, on the market. Lonza can support you through the complicated
authorisation process for your products by:
- Providing information, analytical methods and
advice for our broad portfolio of actives that may be used in your
- Providing opportunities to market and/or
produce a range of disinfectant formulations that we intend to support through
the product authorisation process of the BPR for specified EU Member States.
These formulations could easily be added into your product range and marketed
under your own trade name.